Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.IC50 value:Target: PDE4
[1]. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking• Br J Pharmacol. 2008 Oct;155(3):288-90. [2]. Study of Oglemilast for the Prevention of Asthma. [3]. Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD) [4]. Study of Oglemilast for the Treatment of Asthma
















